The Clinical Impact of the Systemic Immune-inflammation Index in Esophageal Cancer Patients Receiving Curative Treatment.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-11-01 DOI:10.21873/anticanres.17327

Ryuki Esashi, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Sosuke Yamamoto, Mamoru Uchiyama, Koji Numata, Shinnosuke Kawahara, Keisuke Kazama, Ayako Tamagawa, Aya Saito, Norio Yukawa

{"title":"The Clinical Impact of the Systemic Immune-inflammation Index in Esophageal Cancer Patients Receiving Curative Treatment.","authors":"Ryuki Esashi, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Sosuke Yamamoto, Mamoru Uchiyama, Koji Numata, Shinnosuke Kawahara, Keisuke Kazama, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/anticanres.17327","DOIUrl":null,"url":null,"abstract":"Background/aim: The systemic immune-inflammation index (SII) is a calculated biomarker developed to predict the prognosis of malignant tumors. This study evaluated the influence of the SII in patients with esophageal cancer (EC) who underwent curative resection.Patients and methods: Patients who underwent radical esophagectomy and lymph node dissection for EC were enrolled. The SII was calculated as follows: neutrophil count (cell/mm3) × platelet count (cell/mm3 ×103)/lymphocyte count (cell/mm3). The SII, patient characteristics, overall survival (OS), and recurrence-free survival (RFS) were assessed.Results: A total of 180 patients were included in this study. The cutoff value of the SII was set at 500 according to previous studies. Of the 180 patients, 100 were classified into the SII-high group and 80 into the SII-low group. The 3- and 5-year OS rates were 59.0% and 54.0%, respectively, in the SII-high group and 80.0% and 75.0%, respectively, in the SII-low group, showing significant differences between the groups (p=0.001). A multivariate analysis for the OS demonstrated that the SII was an independent prognostic factor (hazard ratio=2.333, 95% confidence interval=1.411-3.860, p<0.001), with similar results obtained for the RFS. Furthermore, hematological recurrence was significantly higher in the SII-high group than in the SII-low group (36.0% vs. 17.5%, p=0.006).Conclusion: The preoperative SII was an independent prognostic factor for OS and RFS in patients with EC who underwent curative resection. Thus, the SII can be a useful marker for the treatment and management of EC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 11","pages":"5035-5041"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17327","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The systemic immune-inflammation index (SII) is a calculated biomarker developed to predict the prognosis of malignant tumors. This study evaluated the influence of the SII in patients with esophageal cancer (EC) who underwent curative resection.

Patients and methods: Patients who underwent radical esophagectomy and lymph node dissection for EC were enrolled. The SII was calculated as follows: neutrophil count (cell/mm³) × platelet count (cell/mm³ ×10³)/lymphocyte count (cell/mm³). The SII, patient characteristics, overall survival (OS), and recurrence-free survival (RFS) were assessed.

Results: A total of 180 patients were included in this study. The cutoff value of the SII was set at 500 according to previous studies. Of the 180 patients, 100 were classified into the SII-high group and 80 into the SII-low group. The 3- and 5-year OS rates were 59.0% and 54.0%, respectively, in the SII-high group and 80.0% and 75.0%, respectively, in the SII-low group, showing significant differences between the groups (p=0.001). A multivariate analysis for the OS demonstrated that the SII was an independent prognostic factor (hazard ratio=2.333, 95% confidence interval=1.411-3.860, p<0.001), with similar results obtained for the RFS. Furthermore, hematological recurrence was significantly higher in the SII-high group than in the SII-low group (36.0% vs. 17.5%, p=0.006).

Conclusion: The preoperative SII was an independent prognostic factor for OS and RFS in patients with EC who underwent curative resection. Thus, the SII can be a useful marker for the treatment and management of EC.

查看原文本刊更多论文

接受根治性治疗的食管癌患者全身免疫炎症指数的临床影响

背景/目的：全身免疫炎症指数（SII）是一种计算得出的生物标志物，用于预测恶性肿瘤的预后。本研究评估了SII对接受根治性切除术的食管癌（EC）患者的影响：患者和方法：研究对象为接受根治性食管切除术和淋巴结清扫术的食管癌患者。SII的计算方法如下：中性粒细胞计数（细胞/立方毫米）×血小板计数（细胞/立方毫米×103）/淋巴细胞计数（细胞/立方毫米）。对 SII、患者特征、总生存期（OS）和无复发生存期（RFS）进行评估：本研究共纳入 180 例患者。根据以往的研究，SII 的临界值定为 500。在 180 例患者中，100 例被归入 SII 高组，80 例被归入 SII 低组。SII高组的3年和5年OS率分别为59.0%和54.0%，SII低组的3年和5年OS率分别为80.0%和75.0%，组间差异显著（P=0.001）。OS的多变量分析表明，SII是一个独立的预后因素（危险比=2.333，95%置信区间=1.411-3.860，P结论：在接受根治性切除术的EC患者中，术前SII是OS和RFS的独立预后因素。因此，SII可作为治疗和管理EC的有用指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.